MilliporeSigma Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has announced the signing of a definitive agreement to acquire Mirus Bio for US$ 600 million. Mirus Bio, part of Gamma Biosciences, is a life science company based in Madison, Wisconsin, USA that specializes in the development and commercialization of transfection reagents, such as TransIT-VirusGENĀ®. Transfection reagents play a critical role in the production of viral vector-based gene therapies.

Read the full article: MilliporeSigma Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing //

Source: https://www.businesswire.com/news/home/20240523946881/en/MilliporeSigma-Signs-Definitive-Agreement-to-Acquire-Mirus-Bio-Furthering-Ambition-to-Be-a-Leading-Supplier-for-Viral-Vector-Manufacturing

Scroll to Top